(HealthDay)—Teprotumumab is associated with better outcomes than placebo among patients with active thyroid eye disease, according to a study published in the Jan. 23 issue of the New England Journal of Medicine.
Read More
(HealthDay)—Teprotumumab is associated with better outcomes than placebo among patients with active thyroid eye disease, according to a study published in the Jan. 23 issue of the New England Journal of Medicine.
Read More
Health Rss 